CNTY-101 is under clinical development by Century Therapeutics and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase I drugs for Primary Mediastinal B-Cell Lymphoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CNTY-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CNTY-101 overview

CNTY-101 (CAR-iNK cell therapy) is under development for the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma, mantle cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma, marginal zone lymphoma and systemic lupus erythematosus. The therapeutic candidate (CAR-NK cell therapy) comprises allogeneic induced pluripotent stem cells (iPSC)-derived natural killer cells which are genetically engineered to express chimeric antigen receptors (CAR) targeting CD19 expressing tumor cells. It is being developed based on iPSC derived Allo-Evasion technology and is administered through intravenous route.

Century Therapeutics overview

Century Therapeutics is a biotechnology company. It develops cell therapies for the treatment of cancer. The company’s major product portfolio includes CNTY-101, CNTY-102, CNTY-104, CNTY-106 and CNTY- 107. Century Therapeutics products treat B-cell malignancies, glioblastoma, acute myeloid leukemia, multiple myeloma, solid tumors and hematological malignancies. It also offers cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived NK and T cell therapies for both hematological and solid tumor malignancies. Century Therapeutics is headquartered in Philadelphia, Pennsylvania, the US.

For a complete picture of CNTY-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.